Hhlr Advisors, Ltd. Bei Gene, Ltd. Transaction History
Hhlr Advisors, Ltd.
- $4.36 Billion
- Q3 2024
A detailed history of Hhlr Advisors, Ltd. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Hhlr Advisors, Ltd. holds 5,176,906 shares of BGNE stock, worth $952 Million. This represents 26.65% of its overall portfolio holdings.
Number of Shares
5,176,906
Previous 5,176,906
-0.0%
Holding current value
$952 Million
Previous $739 Million
57.36%
% of portfolio
26.65%
Previous 19.1%
Shares
3 transactions
Others Institutions Holding BGNE
# of Institutions
252Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$1.94 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.18 Billion0.29% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$914 Million0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$681 Million0.64% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.7MShares$496 Million0.07% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $19.1B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...